]>
IRCT20180921041080N1 IRCT 2018-11-30 Kurdistan University of Medical Sciences The effect of L-carnitine in the treatment of anemia L-carnitine effects on anemia improvement in patients undergoing hemodialysis 2018-11-22 anticipated 100 Complete https://irct.ir/trial/34002 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random allocation method was used to assign participants in blocks of four. There are six probabilities for block size of four (six cards). A hundred participants were assigned randomly using the cards twenty-five times. AABB ABAB BBAA BAAB ABBA BABA The first choice was done using simple randomizing method and table of random numbers. Having selected the first card, other participants are selected according to the rounds. Cards labelled (A) referred to intervention group, and cards labelled (B) referred to control group. Therefore, fifty participants are assigned in each group (intervention and control). Sampling will continue until all the participants are assigned in the groups randomly, Blinding description: Patients in both the intervention and control groups and the nurses who provide the drug and the drug to the patients will not be aware of the type of drug. The placebo was similar to the drug in terms of shape, color, size, weight and packaging. 3 Chronic renal Disease. Intervention 1: Intervention group: Patients in the intervention group will treated for 12 weeks with a single daily dose of L-carnitine tablets containing one gram of L-carnitine tartrate produced by the Karen Pharmaceutical Company. The tablet will be taken with a glass of water after meals. Intervention 2: Control group: The patients of the control group were treated by placebo, which resembles L.Carnitine tablets with a dose of 1 gram completely, made by Karen Pharmaceutical Company one daily after meal for 12 weeks. Yes - There is a plan to make this available What will be shared: Regarding the fact that the present study has been registered as a research project in the “Research Management System of Medical Sciences University of Kurdistan”, it is required to present and register the final report in the “National Health Research Results Database”. Therefore, the sharing process of this study will be done step by step accordingly. It is essential to mention than the results of this study will be published in terms of statistical data, tables and figures in the extracted paper. When: One year To whom: Everyone Conditions: After publishing article Where to obtain: Regarding the fact that presenting and registering the results of the study in a profile on “National Health Research Database” of Medical Sciences University of Kurdistan, and publishing the final paper and registering the researchers’ information in the mentioned database, it will be possible to contact the researchers through emailing and deputy of research and technology of the university. How to obtain: The researchers will be willing to respond emails requesting information, which is not considered confidential and private, about the patients being studied. This is also possible through contacting deputy of research and technology of the university. Comments:
public Anvar Mohamadi Baneh
Pasdaran Avn.
Sanandaj Iran (Islamic Republic of) 1344666177 +98 87 3328 7100 dr.khorshidy@gmail.com Kurdistan University of Medical Sciences scientific Anvar Mohamadi Baneh
Pasdaran Avn.
Sanandaj Iran (Islamic Republic of) 1344666177 +98 87 3328 7100 dr.khorshidy@gmail.com Kurdistan University of Medical Sciences Iran (Islamic Republic of) Patients undergoing hemodialysis Having anemia Hemodialysis more than one year Age more than 20 years 20 years 74 years Both Having infectious, hepatic, and cancer diseases Previous use of L-carnitine supplement Use of corticosteroids Narcotic drugs, alcohol, and cigarette consumption N18.5 Chronic kidney disease, stage 5 Treatment - Drugs Placebo Intervention group: Patients in the intervention group will treated for 12 weeks with a single daily dose of L-carnitine tablets containing one gram of L-carnitine tartrate produced by the Karen Pharmaceutical Company. The tablet will be taken with a glass of water after meals. Control group: The patients of the control group were treated by placebo, which resembles L.Carnitine tablets with a dose of 1 gram completely, made by Karen Pharmaceutical Company one daily after meal for 12 weeks. Anemia. Timepoint: Mean serum hemoglobin, ferritin and iron levels are measured at the beginning and three months after the start of treatment. Method of measurement: Blood sampling. Kurdistan University of Medical Sciences Approved 2018-02-21 ٍEthics committee of Kurdistan University of Medical Sciencess Pasdaran Ave Sanandaj Kurdistan Iran (Islamic Republic of)